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Abstract
Sigma (s) receptors have recently been identified as potential targets for the development of novel therapeutics
aimed at mitigating the effects of methamphetamine. Particularly, s receptors are believed to mitigate some of
the neurotoxic effects of methamphetamine through modulation of dopamine, dopamine transporters and body
temperature. Furthermore, recent evidence suggests that targeting s receptors may prevent cognitive impair-
ments produced by methamphetamine. In the present study, an optimized s receptor antagonist, AZ66, was
evaluated against methamphetamine-induced neurotoxicity and cognitive dysfunction. AZ66 was found to be
highly selective for s receptors compared to 64 other sites tested. Pretreatment of male, Swiss Webster mice with
i.p. dosing of AZ66 significantly attenuated methamphetamine-induced striatal dopamine depletions, striatal
dopamine transporter reductions and hyperthermia. Additionally, neurotoxic dosing with methamphetamine
caused significant memory impairment in the object recognition test, which was attenuated when animals were
pretreated with AZ66 ; similar trends were observed in the step-through passive avoidance test. Taken together,
these results suggest that targeting s receptors may provide neuroprotection against the neurotoxicity and
cognitive impairments produced by methamphetamine.
Received 21 April 2012 ; Reviewed 13 June 2012 ; Revised 2 July 2012 ; Accepted 3 July 2012 ;
First published online 29 August 2012
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Introduction
Methamphetamine is an addictive psychostimulant
and currently listed as the second most abused illicit
substance in the world (United Nations, 2007).
Methamphetamine abuse can result in several negative
consequences, including significant neurotoxicity at high
or repeated doses (Cadet & Krasnova, 2009 ; Kita et al.
2003). Chronic use results in long-lasting nerve terminal
degeneration in specific regions of the brain (Cadet &
Krasnova, 2009). Methamphetamine is believed to exert
these effects through its interaction with monoamine
transporters, primarily in the dopaminergic system
(Krasnova & Cadet, 2009 ; Schep et al. 2010; Sora et al.
2009). This results in the release of dopamine from
synaptic vesicles within the nerve terminal and a
resulting release of excess dopamine into the synapse by
inhibition of reuptake and reversal of flow through
dopamine transporters (DATs; Krasnova & Cadet, 2009;
Schep et al. 2010). This is believed to lead to nerve ter-
minal degeneration through the formation of reactive
oxygen species and reactive nitrogen species (Kita et al.
2003).
The neurotoxic effects of methamphetamine appear
to have significant clinical implications, as neurological
deficits have been found in human clinical populations of
chronic methamphetamine abusers (McCann et al. 1998;
Schep et al. 2010; Volkow et al. 2001a, b ; Wilson et al. 1996).
In addition, it has been documented that significant and
long-lasting nerve terminal degeneration can occur in
these patients (McCann et al. 1998; Wilson et al. 1996),
potentially resulting in cognitive impairments (Hart
et al. 2012). The role of methamphetamine abuse in cog-
nitive-related decline has remained controversial. How-
ever, current studies suggest that, while acute use of
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methamphetamine may actually improve memory and
attention, chronic use results in decreases in memory and
reaction speed (Hart et al. 2012). Methamphetamine-
induced cognitive impairment has been observed both
in humans via clinical tests such as the Wisconsin Card
Sorting Test and animal studies, which evaluate maze
sequential learning (Chapman et al. 2001), motor per-
formance (Walsh & Wagner, 1992), spatial impairment
(Friedman et al. 1998) and object recognition (Belcher et al.
2008; Bisagno et al. 2002; Kamei et al. 2006; O’Dell et al.
2011; Reichel et al. 2012). It is hypothesized that meth-
amphetamine use may increase an abuser’s risk of
neurodegenerative diseases such as Parkinson’s disease
(Callaghan et al. 2010; Kuehn, 2011 ; Morrow et al. 2011).
While these cognitive effects of methamphetamine have
primarily been studied in the hippocampal regions of the
brain, recent evidence has shown that the striatum plays
an important role in memory (Sadeh et al. 2011) and
striatal dopaminergic deficits are evident in patients with
Parkinson’s disease (Altgassen et al. 2007; Beste et al.
2009).
Previous work has demonstrated that sigma (s) re-
ceptors may be a viable target to attenuate some of
the effects of methamphetamine. Methamphetamine in-
teracts with both s1 and s2 receptors at physiologically
relevant concentrations (2¡0.3 and 47¡10 mM, respect-
ively ; Nguyen et al. 2005) and s receptors have been
shown to be involved in many of the behavioural and
physiological effects of methamphetamine (Kaushal &
Matsumoto, 2011; Kaushal et al. 2011, 2012; Matsumoto
et al. 2008; Seminerio et al. 2011, 2012). Pretreatment
with selective s1/s2 receptor antagonists such as AC927
(N-phenethylpiperdine oxalate) or CM156 (3-(4-(4-cyclo-
hexylpiperazin-1-yl)butyl)benzo[D]thiazole-2(3H)-thione)
have been shown to attenuate methamphetamine-
induced hyperthermia, dopaminergic neurotoxicity and
serotonergic neurotoxicity, in addition to mitigating
some of the stimulant effects of methamphetamine, such
as increases in locomotor activity (Kaushal et al. 2011;
Matsumoto et al. 2008). Other reports have shown that
activation of s receptors can provide anti-amnesic and
neuroprotective effects in various models of cognitive
dysfunction (van Waarde et al. 2011) and s receptors are
thought to have a functional role in Parkinson’s disease
(Mishina et al. 2005).
The current study utilized AZ66 (3-(4-(4-cyclohex-
ylpiperazin-1-yl)pentyl)-6-flourobenzo[D]thiazol-2(3H)-
one), a mixed s1/s2 antagonist derived from CM156 and
optimized for metabolic stability (Seminerio et al. 2011), to
determine its effects as a pretreatment against metham-
phetamine-induced hyperthermia, striatal dopaminergic
neurotoxicity and cognitive dysfunction. AZ66 has pre-
viously been shown to mitigate many of the behavioural
effects of methamphetamine, including the development
and expression of behavioural sensitization (Seminerio
et al. 2012), suggesting its potential importance toward
future drug development studies. This study is the first to
evaluate a selective s receptor antagonist for its ability to
attenuate cognitive impairment following repeated meth-
amphetamine administration.
Method
Receptor binding studies
To evaluate the overall selectivity of AZ66 for s receptors,
the compound was subject to NOVAScreen (Caliper
Life Sciences, USA) at targets not previously reported
(Seminerio et al. 2012). Further details of each assay
condition can be accessed through their website (www.
caliperls.com).
Animals
Male, Swiss Webster mice (21–30 g; Harlan, USA) were
used for all experiments. Animals were housed 1–5 per
cage with a 12:12 h light/dark cycle (lights on 06:00
hours) and ad libitum food and water. They were allowed
1 wk to acclimatize following their arrival before being
used in an experiment. All procedures were approved by
the Institutional Animal Care and Use Committee at West
Virginia University.
Drugs and treatment
(+)-Methamphetamine hydrochloride was purchased
from Sigma-Aldrich (USA) and sterile saline solution was
purchased from Teknova (USA). The s receptor antag-
onist, AZ66, was synthesized as previously described
(Seminerio et al. 2012). All drug solutions were made with
saline and the solution volumes were administered rela-
tive to body weight (0.1 ml/10 g).
Mice were randomly divided into groups that were
injected with saline (0.1 ml/10 g i.p.) or AZ66 (10 mg/kg
i.p.) 15 min prior to injection with saline or methamphe-
tamine (5 mg/kg i.p.). The dose of AZ66 was chosen
based on previous studies, which demonstrated signifi-
cant effects against methamphetamine while exerting no
effects on its own (Seminerio et al. 2012). Similarly, pre-
vious work in our lab has shown neurotoxic dosing with
methamphetamine produces a dose-dependent depletion
of dopamine levels in the mouse striatum, with 5 mg/kg
being the lowest dose producing statistically significant
effects (Kaushal et al. 2011). Therefore, 10 mg/kg AZ66
and 5 mg/kg methamphetamine were used.
Each group of mice received their treatment a total of
four times at 2 h intervals. One hour after each treatment,
the body temperatures of the mice were recorded. To
allow sufficient time for the methamphetamine-induced
degeneration of nerve terminals to occur, the animals
were killed and the brains removed 1 wk later (Cappon
et al. 2000). The striata of the mice were then collected
on ice and evaluated for dopamine levels and DAT ex-
pression. The detailed procedure for each of the end-
points is provided below.
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Dopamine assays
Mice (n=6–8/group) were randomly assigned to one of
the following treatments : (1) saline+saline ; (2) saline+
methamphetamine (5 mg/kg i.p.) ; (3) AZ66 (10 mg/kg
i.p.)+saline ; (4) AZ66 (10 mg/kg i.p.)+methampheta-
mine (5 mg/kg i.p.). The mice received their designated
treatments a total of four times at 2 h intervals. One week
later, the striatum was dissected from the mice and then
frozen in liquid nitrogen. The tissues were stored at
x80 xC for later analysis of dopamine content.
Using a dopamine research enzyme immunoassay kit
and protocols provided by the manufacturer (Rocky
Mountain Diagnostics, USA), mouse brain striatal dopa-
mine was quantified. Brain tissues were homogenized in
0.01 N HCl. Dopamine was extracted and then acylated
to N-acyldopamine using the buffer and reagents pro-
vided by the enzyme-linked immunosorbent assay
(ELISA) kit. Acylated dopamine from the tissue samples
was then incubated with solid phase bound dopamine,
dopamine antiserum and antiserum buffer to compete for
a fixed number of antiserum binding sites. Free antigen
and free antigen-antiserum complexes were removed
via the wash buffer. The antibody bound to the solid
phase dopamine was detected using an anti-rabbit IgG-
peroxidase conjugate with 3,3k,5,5k-tetramethylbenzidine
as the substrate. The amount of antibody bound to the
solid phase dopamine was measured by monitoring
the reaction at 450 nm. The solid phase dopamine
measured was inversely proportional to the dopamine
concentration of the tissue sample and was quantified
relative to a standard curve of known concentrations.
DAT immunohistochemistry
Striatal sections were assessed for DAT expression.
Mice (n=4/group) were randomly assigned to one
of the following treatment groups : (1) saline+saline ;
(2) saline+methamphetamine (5 mg/kg i.p.) ; (3) AZ66
(10 mg/kg i.p.)+methamphetamine (5 mg/kg i.p.) ;
(4) AZ66 (10 mg/kg i.p.)+saline. The mice received their
treatments at 2 h intervals, a total of four times. One week
following treatment, the mice were perfused transcar-
dially with 0.1 M phosphate buffered saline (pH 7.4), fol-
lowed by 4% paraformaldehyde. The brains were further
fixed overnight in 4% paraformaldehyde. Coronal sec-
tions (50 mm) of the fixed tissue were made throughout
the rostral-caudal extent of the striatum using a cryostat
and processed in a free-floating state in 0.1 M Tris-HCl
buffered saline (TBS, pH 7.5). The sections were treated
with 0.3% H2O2 in TBS for 30 min at room temperature.
The sections were then treated with TBS containing 0.2%
Triton X-100 and 1.5% normal goat serum for 30 min at
room temperature. Incubation of the sections with rat
anti-mouse DAT antibody (MAB369, dilution 1:10 000;
Chemicon International, USA) was performed for 36 h at
4 xC. The labelled sections were then washed twice in
TBS and processed using Vectastain Elite ABC (Vector
Laboratories, USA). Sections were then incubated with
biotinylated secondary anti-rat antisera (ab6844, dilution
1:200 ; Abcam, USA) in TBS for 60 min. This was then
followed by incubation of the sections with avidin-
biotinylated peroxidase substrate in TBS for 60 min. The
staining was then visualized by reacting 3,3k-diamino-
bendine containing 0.01% H2O2 for 5 min.
The stained sections were mounted onto gelatine-
coated slides and dried. The sections were then dehy-
drated, cleared and coverslipped. The images were
captured digitally using a Zeiss Axiovert 40 microscope
(Carl Zeiss Microscopy, USA) and optical density read-
ings were quantified in anterior regions of the striatum
using ImageJ software (National Institutes of Health,
USA). To obtain the data point for a given animal, at least
two sections per mouse brain were processed and the
optical density readings from the striatal region of each
section were averaged.
Body temperature
Mice (n=6–8/group) were randomly assigned to treat-
ment groups, which were the same as those described for
the dopamine assays. All of the combinations of drug
treatments were given i.p. at 2 h intervals a total of four
times. Core body temperature was measured 1 h follow-
ing each of the treatment combinations with a Thermalert
TH-S monitor (Physitemp Instruments Inc., USA).
During the temperature measurements, mice were gently
held at the base of the tail and a probe (RET-3) was in-
serted approximately 2.5 cm past the rectum into the co-
lon for 8–10 s until a rectal temperature was maintained
for 3–4 s.
Memory measurements
Mice (n=10/group) were randomly assigned to treat-
ment groups, which were the same as those described for
the neurotoxicity studies. All of the combinations of drug
treatments were given i.p. at 2 h intervals a total of four
times. Following 1 wk, animals were evaluated for
memory in the object recognition test and step-through
passive avoidance test. The detailed procedure for each of
the tests is provided below.
Object recognition test
The test was carried out as described previously (Li et al.
2011). Each mouse was allowed to move freely in an
open-field box for 5 min as habituation. Twenty-four
hours later, mice were individually placed in the centre
of the box containing two identical objects (Lego blocks)
located in the two diagonal corners. The cumulative time
spent exploring each object was recorded during a 5 min
period. Exploration was defined as actively touching or
facing (within 2 cm toward) the object. One day later
(24 h after training), mice were tested for memory using
the same procedure except that one of the familiar objects
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was replaced with a novel object. The time of exploration
of each object [Tf and Tn for familiar (f) and novel (n)
objects, respectively] was recorded for determination of
the recognition index (RI)=Tn/(Tf+Tn).
Step-through passive avoidance test
The test was performed as described previously (Zhang
et al. 2005) with some modifications. The apparatus
(Model E10–16SC; Coulbourn Instruments, USA)
consisted of a two-compartment chamber with an il-
luminated compartment connected to a darkened com-
partment by a guillotine door. The experiment consisted
of single training and testing sessions.
On the first day, the animal was placed in the chamber
and allowed to roam freely between the illuminated and
darkened side for 5 min. During training (24 h later), the
mouse was placed in the illuminated compartment,
facing away from the closed guillotine door, for 1 min
before the door was raised. The latency to enter the dar-
kened compartment was recorded. After the mouse en-
tered the darkened compartment, the door was closed
and an electric shock (0.4 mA, 5 s) was delivered from the
steel-rod floor. This was repeated until the latency for the
animal to enter the dark compartment exceeded 60 s once
the door was open. The number of shocks the animal re-
ceived before meeting the >60 s criterion was also re-
corded.
Twenty-four hours later, mice began the testing ses-
sion. To begin the test, the mouse was again placed in the
illuminated compartment, with the guillotine door closed
for 1 min. After 1 min, the door was opened and the re-
tention latency to enter the darkened compartment was
recorded for up to 300 s, at which time the test was ter-
minated. No shocks were delivered to mice that entered
the darkened compartment during the test trial.
Data analysis
The data from the dopamine assays, immuno-
histochemical studies, core body temperature readings,
object recognition test and step through passive avoid-
ance test were evaluated using one-way analysis of
variance (ANOVA). Post-hoc analyses were performed
with Tukey’s tests for pairwise comparisons. For all
analyses, p<0.05 was considered statistically significant.
GraphPad Prism (USA) was used for all data analyses.
Results
Radioligand binding assays
Table 1 summarizes the affinities of AZ66 for radioligand
binding sites. Previous reports showed that AZ66 had
high affinity for both s1 and s2 receptors in the nanomolar
and subnanomolar range (Seminerio et al. 2012).
Compared to its high affinity for s receptors, AZ66 dis-
played a >100-fold preference relative to all 64 non-s
binding sites tested.
Neurotoxicity evaluations
Dopamine assays
Figure 1 shows the effects of the s receptor antagonist
AZ66 on methamphetamine-induced dopamine deple-
tions in the mouse striatum. ANOVA confirmed signifi-
cant differences between groups (F3,36=13.67, p<0.001).
Post-hoc Tukey’s tests confirmed that methamphetamine
produced significant decreases in striatal dopamine
levels compared to saline-treated animals (q=6.17,
p<0.001) and pretreatment with AZ66 significantly atte-
nuated methamphetamine-induced dopamine depletions
(q=8.88, p<0.001). When AZ66 was administered alone,
the striatal dopamine levels were not significantly chan-
ged compared to saline-treated animals (p>0.05).
DAT immunohistochemistry
To test the effects of AZ66 on methamphetamine-induced
DAT reductions, immunohistochemical analyses were
conducted. Figure 2 depicts the effects of methampheta-
mine and AZ66 on DAT immunoreactivity in the mouse
striatum, with a significant difference between the treat-
ment groups (F3,88=118.70, p<0.0001). Post-hoc Tukey’s
multiple comparisons test confirmed that methampheta-
mine caused a significant reduction in DAT im-
munoreactivity relative to treatment with saline alone
(q=25.55, p<0.001). Pretreatment with AZ66 signifi-
cantly attenuated methamphetamine-induced neurotoxi-
city (q=20.97, p<0.001), whereas treatment with AZ66
alone had no significant effects on DAT expression com-
pared to saline alone (q=3.65, p>0.05).
Hyperthermia
Methamphetamine produced a significant increase in
body temperature, which was attenuated by AZ66. One-
way ANOVA showed significant differences between all
groups (F3,15=19.08, p<0.001). ANOVA of body tem-
perature measured following each treatment time-point
revealed significant changes in all but the first-time point
(BT1) (Fig. 3) : BT1 (F3, 39=9.67, p>0.05) ; BT2 (F3, 39=
13.93, p<0.01) ; BT3 (F3, 39=14.02, p<0.01) ; BT4 (F3, 39=
21.14, p<0.01). Post-hoc Tukey’s tests confirmed that
methamphetamine significantly increased body tem-
perature after the second injection onwards (BT2, q=8.09,
p<0.001 ; BT3, q=7.72, p<0.001; BT4, q=8.36, p<0.001).
AZ66 significantly mitigated the hyperthermic effects of
methamphetamine (BT3, q=5.20, p<0.01 ; BT4, q=5.11,
p<0.01). When AZ66 was administered in the absence of
methamphetamine, ANOVA showed that there were no
significant changes in basal body temperature compared
to saline-treated animals (q=1.56, p>0.05).
Memory measurements
Object recognition
The effects of methamphetamine and AZ66 on recog-
nition memory were evaluated in Fig. 4. ANOVA showed
1036 M. J. Seminerio et al.
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Table 1. Binding affinities of AZ66
Radioligand Non-specific binding Tissue or cell Ki
Sigma (s) receptors
s1 5 nM [
3H](+)-pentazocine 10 mM haloperidol Rat brain 2.4¡0.63
s2 3 nM [
3H]di-o-tolylguanidine 10 mM haloperidol Rat brain 0.51¡0.15
Neurotransmitter related
Adenosine 4.0 nM [3H]NECA 1 mM NECA Bovine striatum >10 000
Adrenergic, a1 0.3 nM [3H]7-MeOxy-Prazosin 1 mM phentolamine mesylate Rat forebrain >100
Adrenergic, a2 1 nM [3H]Rx 821002 1 mM phentolamine mesylate Rat cortex >100
Adrenergic, b1 0.04 nM [125I](-) iodocyanopindolol 3 mM alprenolol Human neuroepithelioma >10 000
Cannabinoid, CB1 0.5 nM [3H]CP 55940 1 mM HU-210 Human recombinant
HEK293 cells
>10 000
Cannabinoid, CB2 0.5 nM [3H]CP 55940 1 mM HU-210 Human recombinant
CHO cells
>10 000
Dopamine D4.2 0.15 nM [3H]spiperone 1 mM haloperidol Human recombinant
CHO cells
>100
GABA A, agonist site 5 nM [3H]GABA 1 mM GABA Bovine cerebellum >10 000
GABA A, BDZ a 1 1 nM [3H]flunitrazepam 0.5 mM flumazenil Bovine cortex >10 000
GABA-B 1 nM [3H]CGP 54626A 100 mM baclofen Rat cerebral cortex >10 000
Glutamate, AMPA 5 nM [3H]AMPA 100 mM AMPA Rat forebrain >10 000
Glutamate, kainate 10 nM [3H]kainic acid 10 mM kainic acid Rat forebrain >10 000
Glutamate, NMDA agonist 2 nM [3H]CGP 39653 300 mM NMDA Rat forebrain >10 000
Glutamate, NMDA glycine 4 nM [3H]MDL-105,519 3 mm MDL-105,519 Rat cortex/hippocampus >10 000
Glutamate, NMDA/PCP 10 nM [3H]TCP
5 nM [3H]TCP
100 mM (+)-MK801
10 mM cyclazocine
Rat forebrain
Rat brain
>10 000
>10 000
Glutamate, mGluR1 20 nM [3H]quisqualic acid 1 mM L-glutamate Rat cerebellum >10 000
Glutamate, mGluR5 10 nM [3H]MPEP 10 mM MPEP Rat brain >10 000
Glycine, strychnine 16 nM [3H]strychnine 100 mM strychnine nitrate Rat spinal cord >10 000
Histamine H1 2 nM [
3H]pyrilamine 10 mM triprolidine Bovine cerebellum >100
Histamine H2 0.1 nM [
125I]aminopotentidine 3 mM tiotidine Guinea pig striatum >100
Histamine H3 0.2 nM [
3H]N-a-MeHistamine 100 nM R(-)a-methylhistamine Rat forebrain >100
Muscarinic, central 0.15 nM [3H]QNB 0.1 mM atropine Rat cerebral cortex >100
Muscarinic, peripheral 0.3 nM [3H]QNB 0.1 mM atropine Guinea pig bladder >100
Muscarinic M1 0.5 nM [
3H]N-methyl scopolamine 1 mM (x)scopolamine Human recombinant
CHO cells
>100
Muscarinic M2 0.5 nM [
3H]N-methyl scopolamine 1 mM methylscopolamine Human recombinant
CHO cells
>100
Nicotinic, muscle 1 nM [125I]a-bungarotoxin 10 mM nicotine Human TE671 cells >10 000
Nicotinic, neuronal 0.05 nM [3H]epibatidine 20 nM epibatidine Human SK-N-F1 cells >10 000
Opioid, k 1 0.75 nM [3H]U-69593 1 mM U-69593 Guinea pig cerebellum >100
Opioid, m 1 nM [3H]DAMGO 1 mM naloxone Rat forebrain >100
Angiotensin II, AT1 0.06 nM [
125I](Sar1-Ile8)angiotensin 1 mM angiotensin II Human KAN-TS cells >10 000
Angiotensin II, AT2 0.1 nM [
125I]Tyr4-angiotensin II 0.05 mM angiotensin II Bovine cerebellum >10 000
Bradykinin, BK2 0.2 nM [
3H]bradykinin 100 nM bradykinin TFA Guinea pig ileum >10 000
CCK1 0.02 nM [
125I]CCK-8 1 mM CCK-8 Mouse pancreas >10 000
CCK2 0.02 nM [
125I]CCK-8 1 mM CCK-8 Mouse forebrain >10 000
CRF, non-selective 0.1 nM [125I]Tyr0-oCRF 1 mM Tyr0-oCRF Rat cerebral cortex >10 000
Endothelin, ETA 0.033 nM [
125I]endothelin-1 0.1 mM endothelin-1 Human neuroblastoma >10 000
Endothelin, ETB 0.025 nM [
125I]endothelin-1 0.1 mM endothelin-1 Human astrocytoma >10 000
Oestrogen 0.1 nM [125I]3,7b-oestradiol 10 nM 17b-oestradiol Human breast cancer >10 000
Galanin, non-selective 0.07 nM [125I]galanin 100 nM galanin (porcine) Rat brain >10 000
Glucocorticoid 1 nM [3H]dexamethasone 10 mM triamcinolone Human recombinant >10 000
Neurokinin, NK1 1.4 nM [
3H]substance P 1 mM substance P Rat submaxillary gland >10 000
Neurokinin, NK2 (NKA) 0.1 nM [
125I]neurokinin A 1 mM neurokinin A Human recombinan
CHO cells
>10 000
Neurokinin, NK3 (NKB) 0.1 nM [
125I]eledoisin 1 mM eledoisin Rat cerebral cortex >10 000
Oxytocin 1 nM [3H]oxytocin 1 mM oxytocin Rat uterus >10 000
Testosterone, cytosolic 0.5 nM [3H]methyltrienolone 0.7 mM methyltrienolone Human LnCAP cells >10 000
TRH 2 nM [3H](3MeHis2)TRH 10 mM TRH Rat forebrain >10 000
VIP, non-selective 0.05 nM [125I]VIP 1 mM VIP Rat forebrain >10 000
Vasopressin 1 0.5 nM [3H]phenylalanyl- 3,4,5-v 1 mM Arg8-vasopressin Rat liver >10 000
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significant differences between the groups in the object
recognition test (F3,31=9.01, p<0.001). Post-hoc Tukey’s
tests confirmed that methamphetamine produced sig-
nificant impairment of recognition memory when com-
pared to the saline control (q=7.04, p<0.001) ; this was
prevented by pretreatment with AZ66 (q=5.31, p<0.01).
Animals treated with AZ66 alone showed no significant
difference from saline-treated animals (q=2.50, p>0.05).
Step-through passive avoidance test
Figure 5 depicts the effects of methamphetamine and
AZ66 on memory using the step-through passive avoid-
ance test. No significant effects were observed on the %
entries required for acquisition of the passive avoidance
task during training (Fig. 5a) and the 24 h latency to enter
the dark compartment during testing (Fig. 5b) among any
of the groups tested (F3,31=1.03, p>0.05). However, while
not significant, these results demonstrate a similar trend
to that seen with the object recognition, in which animals
treated with methamphetamine alone showed increased
entries into the dark compartment during the testing
period and decreased latency during the testing period.
These tendencies were reduced by pretreatment with
AZ66.
Discussion
The selective s receptor antagonist, AZ66, has been
optimized for metabolic stability and tested against
the stimulant effects of methamphetamine in our pre-
vious study (Seminerio et al. 2012). The current study
Table 1 (cont.)
Radioligand Non-specific binding Tissue or cell Ki
Ion channels :
Calcium, type L
(Benzothiazepine site)
5 nM [3H]diltiazem, cis(+) 10 mM diltiazem Rat cerebral cortex >100
Calcium, type L
(Dihydropyridine site)
0.2 nM [3H]nitrendipine 1 mM nifedipine Rat cerebral cortex >10 000
Calcium, type N 0.01 nM [125I]v-conotoxin GVIA 0.1 mM v-conotoxin GVIA Rat cerebral cortex >10 000
Potassium, ATP-sensitive 0.2 nM [3H]glibenclamide 0.1 mM glibenclamide Rat cerebral cortex >10 000
Potassium, Ca2+ act VI 0.05 nM [125I]apamin 100 nM apamin Rat forebrain >10 000
Sodium, site 2 2 nM [3H]batrachotoxin 1 mM aconitine Rat forbrain >100
Enzymes and other miscellaneous
Acetylcholine esterase 0.3 mM [3H]acethylthiocholine 100 mM physostigmine Human recombinant >100
Choline acetyltransferase 0.2 nM [14C]acetyl coenzyme 0.1 mM Ro 41-1049 Rat cerebral cortex >10 000
Glutamic acid decarboxylase 4 mM [14C]L-glutamic acid 100 mM aminooxy acetic acid Rat striatum >10 000
Leukotriene, LTB4 (BLT) 0.48 nM [
3H]leukotriene B4 500 nM leukotriene B4 Guinea pig spleen >10 000
Leukotriene, LTD4 (CysLT1) 0.2 nM [
3H]leukotriene D4 1 mM leukotriene D4 Guinea pig lung >10 000
MAOA oxidase, peripheral 50 mM [14C]5-HT 1 mM Ro 41-1049 Rat liver mitochondria >10 000
MAOB oxidase, peripheral 10 mM [14C]phenylethylamine 10 mM Ro 16-6491 Rat liver mitochondria >10 000
Nitric oxide, NOS
(neuronal binding)
5 nM [3H]NOARG 100 mM NOARG Rat brain >10 000
Platelet activating factor 1.7 nM [3H]hexadecyl-acetyl-PAF 1 mM C16-PAF Rabbit platelets >10 000
Thromboxane, TXA2 2 nM [
3H]SQ 29,548 10 mM pinane-thromboxane Human platelets >10 000
GABA, c-aminobutyric acid ; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid ; NMDA, N-methyl-D-aspartate ;
PCP, phencyclidine ; Ro 41,1049, N-(2-aminoethyl)-5-(3-fluorophenyl)-4-thiazolecarboxamide ; Ro 16-6491, N-(2-aminoethyl)-
4-chlorobenzamide ; CCK, cholecystokinin ; CRF, corticotrophin releasing factor ; TRH, thyrotropin releasing hormone;
VIP, vasoactive intestinal peptide ; NECA, 5k-N-ethylcarboxamidoadenosine ; Rx 821002, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-
2-yl)-4,5-dihydro-1H-imidazole ; CP 55,940, 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol ;
HU-210, (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol ;
MAO, monoamine oxidase ; CGP 54626A, cyclohexylmethyl-[(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino]-2-
hydroxypropyl]phosphinic acid ; CGP 39653, 2-amino-4-propyl-5-phosphono-3-pentenoic acid ; MDL-105,519,
(E)-4,6-dichloro-3-(2-phenyl-2-carboxyethenyl)indole-2-carboxylic acid ; MK801, (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-di-
benzo[a,d]cyclohepten-5,10-imine hydrogen maleate dizocilpine hydrogen maleate ; TCP,1-(1-(2-thienyl)cyclohexyl)piperidine ;
MPEP, 2-methyl-6-(phenylethynyl)pyridine ; U-69593, (+)-(5a,7a,8b)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-ben-
zeneacetamide ; TFA, trifluoroacetic acid ; QNB, quinuclidinyl benzilate ; DAMGO, (2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydro-
xyphenyl)propanoyl]amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide ; GVIA,
(3-iodotyrosyl22)v-conotoxic ; 5-HT, serotonin ; NOARG, L-NG-nitro-arginine ; PAF, platelet activating factor ; SQ 29,548,
[1S-[1a, 2a(Z),3a,4a]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid ; Affinities
(Ki in nanomolar, mean¡S.E.M.) were determined in tissue or cell homogenates. Values of >100 and >10 000 signify that there was
<50% displacement of the radioligand at that concentration.
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demonstrates that AZ66 has protective effects against
methamphetamine-induced dopaminergic neurotoxicity,
hyperthermia and memory impairment. These findings
are important as AZ66 retained its protective pharmaco-
logical profile and high selectivity for s receptors, fol-
lowing optimization from its parent compound CM156,
deeming it credible as a lead compound for future drug
development.
Consistent with prior studies (Kaushal & Matsumoto,
2011), this work also demonstrates that targeting s re-
ceptors can provide neuroprotective effects. While future
studies will need to be conducted to delineate the exact
mechanism of this interaction, a number of hypotheses
can begin to explain the neuroprotective effects of s re-
ceptor antagonists. Sigma receptors have been shown to
modulate various neurotransmitter systems afflicted by
methamphetamine (Bastianetto et al. 1995; Guitart et al.
2004; Mishina et al. 2005). Specifically, our results further
emphasize a modulatory role of s receptors in the dopa-
minergic system and regions of the brain responsible for
dopamine transmission.
Dopamine depletions following methamphetamine
administration appear primarily dependent on DAT
function (Cadet & Krasnova, 2009 ; Krasnova & Cadet,
2009 ; Pu et al. 1994; Schmidt et al. 1985). Animals lacking
DATs are protected against dopamine depletions
(Fumagalli et al. 1998; Giros et al. 1996). In addition,
striatal dopamine depletions are proportional to the de-
gree of hyperthermia, which is linked to methampheta-
mine-induced lethality (Bowyer et al. 1994). The selective
s receptor antagonist, AZ66, was found to protect against
methamphetamine-induced striatal dopamine and DAT
reductions as well as increases in body temperature.
These neuroprotective properties of AZ66 are likely due
to its ability to modulate body temperature following
methamphetamine exposure. Previous work has demon-
strated that hypothermia can provide neuroprotection
against methamphetamine-induced dopamine deficits
(Bowyer et al. 1994). In addition, earlier studies in our lab
have shown a strong correlation between the ability of s
receptor ligands to mitigate methamphetamine-induced
hyperthermia and dopamingeric neurotoxicity (Kaushal
et al. 2011). These findings support previous studies that
also demonstrate neuroprotective properties of s receptor
antagonists against methamphetamine (Kaushal et al.
2011; Matsumoto et al. 2008; Seminerio et al. 2011).
With evidence linking methamphetamine exposure to
an increased risk for the development of Parkinson’s
disease, dopaminergic neurotoxicity remains a central
theme. A myriad of studies have shown that metham-
phetamine produces significant depletions of dopamine
levels and DATs in both humans and animal models
(Cadet & Krasnova, 2009 ; Kita et al. 2003; Morrow et al.
2011; Schmidt et al. 1985; Volkow et al. 2001a, b ; Wilson et
al. 1996). Furthermore, striatal neurotoxicity, which is the
focus of this study, has been implicated in Parkinson’s
disease and can impact cognitive function (Altgassen et
al. 2007; Beste et al. 2009; Callaghan et al. 2010).
While the majority of research has been dedicated to
the acute effects of methamphetamine on cognitive func-
tion (some showing an increase in cognitive function
following low to moderate doses ; Hart et al. 2012), less
is known regarding the long-term effects of repeated
methamphetamine abuse on cognition. The following
paragraphs will discuss the relationship between re-
peated methamphetamine administration and its effects
on the dopaminergic system and cognitive functioning.
In addition, the functional importance of targeting s re-
ceptors to prevent methamphetamine-induced cognitive
impairments will also be discussed.
A number of neurotransmitter systems are likely in-
volved in methamphetamine-induced memory impair-
ment, including dopamine (Gough et al. 2002; Han & Gu,
2006; Kuczenski et al. 1995). Dopamine has been shown to
modulate different cognitive functions, including mem-
ory, attention, task switching and response inhibition
(Cohen & Servan-Schreiber, 1993 ; Nordahl et al. 2003).
Dopamine deficits in the striatum have been shown to
reduce reaction time and simple task performance
(Baunez & Robbins, 1999 ; Nordahl et al. 2003) while do-
pamine deficits in the prefrontal cortex also contribute to
cognitive dysfunction (Baunez & Robbins, 1999 ; Roberts
et al. 1994; Rogers et al. 1999). Methamphetamine is
known to produce effects in both the striatum and pre-
frontal cortex (Cadet & Krasnova, 2009 ; Kita et al. 2003),
in which s receptors are expressed (Guitart et al. 2004;
Hayashi et al. 2010). In addition, s receptors are thought
to modulate the dopaminergic system (Bastianetto et al.
1995). The s receptor ligands, SA 4503 and AC927, have
both been recently reported to modulate methampheta-
mine-induced dopamine release (Kaushal et al. 2012;
Rodvelt et al. 2011), suggesting a role for s receptors in the
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Fig. 1. Effects of methamphetamine (Meth) and AZ66 on
dopamine (DA) levels in the mouse striatum. Mice were
pretreated with saline (0 mg/kg i.p. AZ66) or AZ66 (10 mg/kg
i.p.). After 15 min, the mice were then treated with saline
(xMeth) or Meth (+Meth, 5 mg/kg i.p.). This treatment
schedule was repeated four times at 2 h intervals. One week
later, the brain was removed and DA levels were measured
using enzyme-linked immunosorbent assay. Data are reported
as mean¡S.E.M. *** p<0.001 vs. saline, ## p<0.001 vs. Meth;
n=6–8 per group.
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dopaminergic effects of methamphetamine. In addition,
other s receptor ligands including CM156, SN79 and
AC927, have all been shown to prevent striatal DAT re-
ductions following methamphetamine exposure while
having no significant effect on striatal DAT expression on
its own (Kaushal et al. 2011; Matsumoto et al. 2008).
The striatum plays an important though often forgot-
ten role in cognition. It has been shown that the striatum
cooperates with the hippocampus in the formation of
episodic memories (Sadeh et al. 2011), which are often
impaired in patients with Parkinson’s disease, and sub-
sequent dopaminergic striatal deficiencies (Altgassen et al.
2007; Beste et al. 2009). Dopamine plays a strong role in
the formation of episodic memories similar to those seen
in the object recognition test (Hotte et al. 2005). Therefore,
it should come as no surprise that neurotoxic doses
of methamphetamine, which significantly lower striatal
dopamine levels, impair object recognition memory
(Belcher et al. 2008; Bisagno et al. 2002; O’Dell et al. 2011;
Reichel et al. 2012; Schroder et al. 2003). In the present
study, pretreatment with AZ66 significantly attenuated
the amnesic effect of neurotoxic methamphetamine in
object recognition, which appears mediated at least in
part through s receptors, as pretreatment with AZ66
also attenuated methamphetamine-induced dopaminer-
gic neurotoxicity in the striatum. It is also possible that
protection of these necessary striatal dopamine stores
resulted in enhanced object recognition memory via an
indirect modulatory role on glutamatergic transmission,
given that striatal dopamine plays a role in modulating
glutamatergic signalling (Marti et al. 2002; Yamamoto &
Davy, 1992), which is important in mediating object rec-
ognition memory (Roullet et al. 2001; Sargolini et al. 2003)
and s receptors can regulate glutamatergic transmission
by functionally modulating the NMDA receptor complex
(Guitart et al. 2004).
The pharmacology and neuroanatomy of object recog-
nition memory is very complex and can rely upon many
brain regions and neurotransmitters. However, recent
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Fig. 2. Effects of methamphetamine (Meth) and AZ66 (AZ) on dopamine transporter (DAT) immunoreactivity in the mouse
striatum. Mice were pretreated with saline (Sal) or AZ (10 mg/kg i.p.). After 15 min, the mice were then treated with Sal or Meth
(5 mg/kg i.p.). This treatment schedule was repeated four times at 2 h intervals. One week later, the brains were removed and
stained for DAT immunoreactivity. A representative section from each treatment group is shown, together with average optical
density readings (mean¡S.E.M.). *** p<0.001 vs. saline, ### p<0001 vs. Meth ; n=4 per group.
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Fig. 3. Effects of AZ66 on methamphetamine (Meth)-induced
hyperthermia. Mice were pretreated with saline or AZ66
(10 mg/kg i.p.) and after 15 min the mice were treated with
saline or Meth (5 mg/kg i.p.). Core body temperature was
measured 1 h after each injection combination. This regimen was
repeated four times at 2 h intervals. Data are reported as
mean¡S.E.M. *** p<0.001 vs. saline, ## p<0.01 vs. Meth ; n=6–8
per group.
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research has implicated the perirhinal cortex as an im-
portant brain region responsible for object recognition
memory (Reichel et al. 2012; Wan et al. 1999; Warburton &
Brown, 2010). While projections between the prefrontal
cortex and hippocampus are thought to contribute to
cognitive memory formation (Hirai et al. 2012; Miyashita
& Chang, 1988), the prefrontal cortex does not directly
project to the hippocampus, but rather to the perirhinal
cortex and amygdala (Burwell, 2001; Furtak et al. 2007;
Hirai et al. 2012). In addition to being expressed in the
prefrontal cortex, s receptors are also located in the
amygdala (Hayashi et al. 2010) and may play a mod-
ulatory role on cognition in these areas (Wang et al. 2007).
The role of the hippocampus in object recognition re-
mains controversial ; however, the putative role is be-
lieved to be evoked when spatial cues or landmarks
present in the room are used by animals while in the
testing chamber (Morris & Frey, 1997). Since our object
recognition testing chamber was enclosed within cur-
tains, the effects of distal landmarks and the role of the
hippocampus in our behavioural protocol can therefore
be minimized.
Consistent with the result in object recognition, treat-
ment with methamphetamine in the absence or presence
of AZ66 produced a similar trend to memory changes in
the step-through passive avoidance test, although the
data were not statistically significant. Dopamine plays
a strong role in different brain regions involved with
the regulation of inhibitory avoidance memory. In the
striatum, pharmacological blockade of dopamine re-
ceptors impairs step-through passive avoidance memory
(Manago et al. 2009). Dopamine infused into the amyg-
dala post-training enhances memory, while dopamine
receptor antagonists impair memory retention in the
passive avoidance test (Lalumiere et al. 2004). In addition,
the dopamine uptake inhibitor GBR 12783 injected before
training significantly improves passive avoidance mem-
ory in rats (Nail-Boucherie et al. 1998). One reason for the
lack of significant results may be due to the strength of
emotional memory created by our behavioural paradigm.
Emotional or fear memory is one of the strongest forms of
memory and also the easiest to learn. In our behavioural
protocol, the mice received a moderately large intensity
and duration of footshocks (0.4 mA/5 s). While this
makes the training portion of the protocol easier, it can
also have an effect of making the memory stronger in all
of the treatments, resulting in a response that can mask
the promnesic effects of the experimental variable or
treatment (Nail-Boucherie et al. 1998; Rossato et al. 2009).
It is possible that training animals with lower intensity
and shorter duration of shocks (e.g. 0.3 mA/2–3 s) may
cause less ‘extreme’ memory and thus allow more sig-
nificance to be observed 24 h later during our testing
paradigm. Nevertheless, our results, taken with the object
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Fig. 4. Effects of AZ66 (AZ) on methamphetamine (Meth)-
induced memory impairment in the object recognition test. Mice
were pretreated with saline (Sal) or AZ (10 mg/kg i.p.). After
15 min, the mice were then treated with Sal or Meth (5 mg/kg
i.p.). This treatment schedule was repeated four times at 2 h
intervals. One week later, the animals underwent the object
recognition test. RI, Recognition Index. Data are reported as
mean¡S.E.M. *** p<0.001 vs. Sal ; ## p<0.01 vs. Meth ; n=10
per group.
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Fig. 5. Effects of AZ66 (AZ) on methamphetamine (Meth)-
induced cognitive impairment in the step-through passive
avoidance test. Mice were pretreated with saline (Sal) or AZ
(10 mg/kg i.p.). After 15 min, the mice were then treated with Sal
or Meth (5 mg/kg i.p.). This treatment schedule was repeated
four times at 2 h intervals. One week later, the animals
underwent the step-through passive avoidance test. Animals
were observed for (a) % entries into the dark compartment
during training and (b) latency to enter dark compartment. Data
were reported as mean¡S.E.M., no significant changes were
observed; n=10 per group.
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recognition data, suggest that methamphetamine may
produce memory impairment in part through s re-
ceptors. While earlier studies have shown cognitive en-
hancement is associated with s receptor agonists after an
insult has occurred (van Waarde et al. 2011), we believe
AZ66 is working by preventing or minimizing cognitive
insult produced by methamphetamine.
In conclusion, the optimized selective s receptor
antagonist AZ66 was found to significantly attenuate
dopaminergic neurotoxicity and memory impairment
produced by repeated exposure to methamphetamine.
Future studies will need to be conducted to further
characterize the role of s receptors in methamphetamine-
induced neurotoxicity and cognitive impairment.
However, our studies, taken with previous literature,
suggest that s receptors represent a promising target
for the development of novel therapeutics aimed at
alleviating a multitude of effects produced by metham-
phetamine.
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